{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:27:20Z","timestamp":1788413240558,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Gastro-oesophageal reflux disease (GORD) is commonly thought to play an important role in chronic cough and patients are often empirically treated with acid suppression therapy. We sought to investigate the response rate to acid suppression treatment in patients with and without heartburn attending two specialist cough clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review of 558 consecutive patients referred to two specialist cough clinics was performed (UK and USA). Patients who were treated with acid suppression were included and their documented response to treatment was collected. Binary logistic regression was used to ascertain the value of reported heartburn in predicting the response of chronic cough to acid suppression therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 558 consecutive referrals, 238 patients were excluded due to missing data or cough duration of\u2009&lt;\u20098\u00a0weeks. The remaining 320 patients were predominantly female (76%), with mean age 61 yrs (\u00b1\u200913) and 96.8% non-smokers, with chronic cough for 36 (18\u2013117) months. Of 72 patients with heartburn, 20 (28%) noted improvement in their cough with acid suppression, whereas of 248 without heartburn, only 35 (14%) responded. Patients reporting heartburn were 2.7 (95% C.I. 1.3\u20135.6) times more likely to respond to acid suppression therapy (p\u2009=\u20090.007).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In specialist cough clinics, few patients report a response of their chronic cough to acid suppression therapy. Nonetheless, heartburn is a useful predictor substantially increasing the likelihood of benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00408-021-00496-w","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T10:02:29Z","timestamp":1637316149000},"page":"597-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Heartburn as a Marker of the Success of Acid Suppression Therapy in Chronic Cough"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-4347","authenticated-orcid":false,"given":"H.","family":"Badri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Satia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Mangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tangaroonsanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"DeVault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"496_CR1","doi-asserted-by":"crossref","unstructured":"Herregods TVK, Pauwels A, Tack J, Smout A, Bredenoord AJ (2017) Reflux-cough syndrome: assessment of temporal association between reflux episodes and cough bursts. Neurogastroenterol Motil 29(12).","DOI":"10.1111\/nmo.13129"},{"key":"496_CR2","doi-asserted-by":"crossref","unstructured":"Houghton LA, Smith JA. Gastro-oesophageal reflux events: just another trigger in chronic cough? Gut. 2017.","DOI":"10.1136\/gutjnl-2017-314027"},{"issue":"6","key":"496_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.chest.2016.08.1458","volume":"150","author":"PJ Kahrilas","year":"2016","unstructured":"Kahrilas PJ, Altman KW, Chang AB, Field SK, Harding SM, Lane AP et al (2016) Chronic cough due to gastroesophageal reflux in adults: CHEST guideline and expert panel report. Chest 150(6):1341\u20131360","journal-title":"Chest"},{"issue":"3","key":"496_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/nmo.12513","volume":"27","author":"C Almansa","year":"2015","unstructured":"Almansa C, Smith JA, Morris J, Crowell MD, Valdramidou D, Lee AS et al (2015) Weak peristalsis with large breaks in chronic cough: association with poor esophageal clearance. Neurogastroenterol Motil 27(3):431\u2013442","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"496_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.gastro.2010.06.050","volume":"139","author":"JA Smith","year":"2010","unstructured":"Smith JA, Decalmer S, Kelsall A, McGuinness K, Jones H, Galloway S et al (2010) Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology 139(3):754\u2013762","journal-title":"Gastroenterology"},{"issue":"1","key":"496_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00408-013-9528-7","volume":"192","author":"PJ Kahrilas","year":"2014","unstructured":"Kahrilas PJ, Smith JA, Dicpinigaitis PV (2014) A causal relationship between cough and gastroesophageal reflux disease (GERD) has been established: a pro\/con debate. Lung 192(1):39\u201346","journal-title":"Lung"},{"issue":"8","key":"496_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrgastro.2016.91","volume":"13","author":"LA Houghton","year":"2016","unstructured":"Houghton LA, Lee AS, Badri H, DeVault KR, Smith JA (2016) Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nat Rev Gastroenterol Hepatol 13(8):445\u2013460","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"496_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1378\/chest.12-1788","volume":"143","author":"PJ Kahrilas","year":"2013","unstructured":"Kahrilas PJ, Howden CW, Hughes N, Molloy-Bland M (2013) Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. Chest 143(3):605\u2013612","journal-title":"Chest"},{"issue":"9","key":"496_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1046\/j.1365-2036.2001.01050.x","volume":"15","author":"S Xue","year":"2001","unstructured":"Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO (2001) Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 15(9):1351\u20131356","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"496_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1572-0241.2003.07304.x","volume":"98","author":"TM Ours","year":"2003","unstructured":"Ours TM, Fackler WK, Richter JE, Vaezi MF (2003) Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 98(3):545\u2013550","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"496_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/01.mlg.0000192173.00498.ba","volume":"116","author":"MF Vaezi","year":"2006","unstructured":"Vaezi MF, Richter JE, Stasney CR, Spiegel JR, Iannuzzi RA, Crawley JA et al (2006) Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 116(2):254\u2013260","journal-title":"Laryngoscope"},{"issue":"2","key":"496_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1365-2036.2010.04511.x","volume":"33","author":"NJ Shaheen","year":"2011","unstructured":"Shaheen NJ, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M et al (2011) Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33(2):225\u2013234","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"496_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.alit.2019.04.011","volume":"68","author":"Y Kanemitsu","year":"2019","unstructured":"Kanemitsu Y, Kurokawa R, Takeda N, Takemura M, Fukumitsu K, Asano T et al (2019) Clinical impact of gastroesophageal reflux disease in patients with subacute\/chronic cough. Allergol Int 68(4):478\u2013485","journal-title":"Allergol Int"},{"issue":"2","key":"496_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJMc1615067","volume":"376","author":"JA Smith","year":"2017","unstructured":"Smith JA, Woodcock A (2017) Chronic cough. N Engl J Med 376(2):183\u2013184","journal-title":"N Engl J Med"},{"key":"496_CR15","doi-asserted-by":"crossref","unstructured":"Ashley Woodcock ECY, Jacky A Smith (2010) New insights in cough. Brit Med Bull (96):12.","DOI":"10.1093\/bmb\/ldq034"},{"issue":"9515","key":"496_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(06)68414-6","volume":"367","author":"RS Irwin","year":"2006","unstructured":"Irwin RS, Gutterman DD (2006) American college of chest physicians\u2019 cough guidelines. Lancet 367(9515):981","journal-title":"Lancet"},{"issue":"1","key":"496_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.chest.2017.10.016","volume":"153","author":"RS Irwin","year":"2018","unstructured":"Irwin RS, French CL, Chang AB, Altman KW (2018) Panel CEC Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. Chest 153(1):196\u2013209","journal-title":"Chest"},{"key":"496_CR18","doi-asserted-by":"crossref","unstructured":"Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, et al (2020) ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Resp J 55(1).","DOI":"10.1183\/13993003.01136-2019"},{"issue":"Suppl 1","key":"496_CR19","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2006.065144","volume":"61","author":"AH Morice","year":"2006","unstructured":"Morice AH, McGarvey L, Pavord I, British Thoracic Society Cough Guideline G (2006) Recommendations for the management of cough in adults. Thorax. 61(Suppl 1):i1-24","journal-title":"Thorax."},{"issue":"1 Suppl","key":"496_CR20","doi-asserted-by":"publisher","first-page":"80S","DOI":"10.1378\/chest.129.1_suppl.80S","volume":"129","author":"RS Irwin","year":"2006","unstructured":"Irwin RS (2006) Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest 129(1 Suppl):80S-94S","journal-title":"Chest"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-021-00496-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T10:07:50Z","timestamp":1637921270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-021-00496-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["496"],"URL":"https:\/\/doi.org\/10.1007\/s00408-021-00496-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-886153\/v1","asserted-by":"object"}]},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAS has received funding for consultancy and research funds from Afferent Pharmaceuticals, Merck Inc., Bayer, Bellus, GSK, Xention Ltd, Ario Pharma Ltd, Glenmark, Almirall, AstraZeneca, Axalbion, Patara, Verona Pharma, NeRRe Pharmaceuticals, Menlo Pharmaceuticals, and Attenua Inc (outside of submitted work). I.S. reports grants from ERS Respire 3 Marie Curie Fellowship, British Medical Association, and North West Lung Centre Charity, grants and personal fees from Merck Canada, and personal fees from GSK and AstraZeneca, outside the submitted work. HB, VB, MAM, AT, KRD, ASL, and LAH have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}